Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer.
Identifieur interne : 004C93 ( PubMed/Corpus ); précédent : 004C92; suivant : 004C94Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer.
Auteurs : A. Burgos ; A. Alcaide ; C. Alcoba ; J M Azcona ; J. Garrido ; C. Lorente ; E. Moreno ; E. Murillo ; J. Olsina-Pavia ; J. Olsina-Kissler ; E. Samaniego ; M. SerraSource :
- Lymphology [ 0024-7766 ] ; 1999.
English descriptors
- KwdEn :
- Arm, Breast Neoplasms (radiotherapy), Breast Neoplasms (surgery), Breast Neoplasms (therapy), Combined Modality Therapy (adverse effects), Coumarins (administration & dosage), Coumarins (adverse effects), Coumarins (therapeutic use), Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Lymphedema (drug therapy), Lymphedema (etiology), Middle Aged, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Coumarins.
- adverse effects : Combined Modality Therapy, Coumarins.
- drug therapy : Lymphedema.
- etiology : Lymphedema.
- radiotherapy : Breast Neoplasms.
- surgery : Breast Neoplasms.
- chemical , therapeutic use : Coumarins.
- therapy : Breast Neoplasms.
- Arm, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Middle Aged, Treatment Outcome.
Abstract
In a randomized, double-blind, parallel group study, we compared the clinical efficacy of coumarin 90 mg/day (Group A) with 135 mg/day (Group B) in 77 women (age 35-65 years) with lymphedema of the upper limb secondary to surgery and irradiation for treatment of breast cancer. During 12 months of coumarin therapy, the arm volume of lymphedema and a clinical score (degree of arm edema, heaviness, hardness, and neuralgia/dysesthesia) were determined. In both groups, the volume of arm lymphedema decreased (14.9% in Group A and 13.2% in Group B) (N.S.), the overall clinical score improved (12.9 +/- 4.3 to 5.7 +/- 3.5 in Group A and from 11.7 +/- 3.7 to 4.7 +/- 3.9 in Group B) (N.S.), and the overall efficacy of coumarin was similarly good or excellent (71.9% in Group A and 68.6% in Group B) (N.S.). Only mild to moderate side effects of drug therapy were recorded. Coumarin prevents a spontaneous trend toward an increase in arm lymphedema after treatment of breast cancer, decreases the severity of local symptoms, and overall improves the quality of life. No difference was found between the apparent benefits of coumarin at 90 mg/day compared with 135 mg/day.
PubMed: 10197321
Links to Exploration step
pubmed:10197321Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer.</title><author><name sortKey="Burgos, A" sort="Burgos, A" uniqKey="Burgos A" first="A" last="Burgos">A. Burgos</name><affiliation><nlm:affiliation>Laboratorios Knoll, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Alcaide, A" sort="Alcaide, A" uniqKey="Alcaide A" first="A" last="Alcaide">A. Alcaide</name></author><author><name sortKey="Alcoba, C" sort="Alcoba, C" uniqKey="Alcoba C" first="C" last="Alcoba">C. Alcoba</name></author><author><name sortKey="Azcona, J M" sort="Azcona, J M" uniqKey="Azcona J" first="J M" last="Azcona">J M Azcona</name></author><author><name sortKey="Garrido, J" sort="Garrido, J" uniqKey="Garrido J" first="J" last="Garrido">J. Garrido</name></author><author><name sortKey="Lorente, C" sort="Lorente, C" uniqKey="Lorente C" first="C" last="Lorente">C. Lorente</name></author><author><name sortKey="Moreno, E" sort="Moreno, E" uniqKey="Moreno E" first="E" last="Moreno">E. Moreno</name></author><author><name sortKey="Murillo, E" sort="Murillo, E" uniqKey="Murillo E" first="E" last="Murillo">E. Murillo</name></author><author><name sortKey="Olsina Pavia, J" sort="Olsina Pavia, J" uniqKey="Olsina Pavia J" first="J" last="Olsina-Pavia">J. Olsina-Pavia</name></author><author><name sortKey="Olsina Kissler, J" sort="Olsina Kissler, J" uniqKey="Olsina Kissler J" first="J" last="Olsina-Kissler">J. Olsina-Kissler</name></author><author><name sortKey="Samaniego, E" sort="Samaniego, E" uniqKey="Samaniego E" first="E" last="Samaniego">E. Samaniego</name></author><author><name sortKey="Serra, M" sort="Serra, M" uniqKey="Serra M" first="M" last="Serra">M. Serra</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1999">1999</date><idno type="RBID">pubmed:10197321</idno><idno type="pmid">10197321</idno><idno type="wicri:Area/PubMed/Corpus">004C93</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004C93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer.</title><author><name sortKey="Burgos, A" sort="Burgos, A" uniqKey="Burgos A" first="A" last="Burgos">A. Burgos</name><affiliation><nlm:affiliation>Laboratorios Knoll, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Alcaide, A" sort="Alcaide, A" uniqKey="Alcaide A" first="A" last="Alcaide">A. Alcaide</name></author><author><name sortKey="Alcoba, C" sort="Alcoba, C" uniqKey="Alcoba C" first="C" last="Alcoba">C. Alcoba</name></author><author><name sortKey="Azcona, J M" sort="Azcona, J M" uniqKey="Azcona J" first="J M" last="Azcona">J M Azcona</name></author><author><name sortKey="Garrido, J" sort="Garrido, J" uniqKey="Garrido J" first="J" last="Garrido">J. Garrido</name></author><author><name sortKey="Lorente, C" sort="Lorente, C" uniqKey="Lorente C" first="C" last="Lorente">C. Lorente</name></author><author><name sortKey="Moreno, E" sort="Moreno, E" uniqKey="Moreno E" first="E" last="Moreno">E. Moreno</name></author><author><name sortKey="Murillo, E" sort="Murillo, E" uniqKey="Murillo E" first="E" last="Murillo">E. Murillo</name></author><author><name sortKey="Olsina Pavia, J" sort="Olsina Pavia, J" uniqKey="Olsina Pavia J" first="J" last="Olsina-Pavia">J. Olsina-Pavia</name></author><author><name sortKey="Olsina Kissler, J" sort="Olsina Kissler, J" uniqKey="Olsina Kissler J" first="J" last="Olsina-Kissler">J. Olsina-Kissler</name></author><author><name sortKey="Samaniego, E" sort="Samaniego, E" uniqKey="Samaniego E" first="E" last="Samaniego">E. Samaniego</name></author><author><name sortKey="Serra, M" sort="Serra, M" uniqKey="Serra M" first="M" last="Serra">M. Serra</name></author></analytic><series><title level="j">Lymphology</title><idno type="ISSN">0024-7766</idno><imprint><date when="1999" type="published">1999</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Arm</term><term>Breast Neoplasms (radiotherapy)</term><term>Breast Neoplasms (surgery)</term><term>Breast Neoplasms (therapy)</term><term>Combined Modality Therapy (adverse effects)</term><term>Coumarins (administration & dosage)</term><term>Coumarins (adverse effects)</term><term>Coumarins (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Lymphedema (drug therapy)</term><term>Lymphedema (etiology)</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Coumarins</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Combined Modality Therapy</term><term>Coumarins</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Coumarins</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Arm</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In a randomized, double-blind, parallel group study, we compared the clinical efficacy of coumarin 90 mg/day (Group A) with 135 mg/day (Group B) in 77 women (age 35-65 years) with lymphedema of the upper limb secondary to surgery and irradiation for treatment of breast cancer. During 12 months of coumarin therapy, the arm volume of lymphedema and a clinical score (degree of arm edema, heaviness, hardness, and neuralgia/dysesthesia) were determined. In both groups, the volume of arm lymphedema decreased (14.9% in Group A and 13.2% in Group B) (N.S.), the overall clinical score improved (12.9 +/- 4.3 to 5.7 +/- 3.5 in Group A and from 11.7 +/- 3.7 to 4.7 +/- 3.9 in Group B) (N.S.), and the overall efficacy of coumarin was similarly good or excellent (71.9% in Group A and 68.6% in Group B) (N.S.). Only mild to moderate side effects of drug therapy were recorded. Coumarin prevents a spontaneous trend toward an increase in arm lymphedema after treatment of breast cancer, decreases the severity of local symptoms, and overall improves the quality of life. No difference was found between the apparent benefits of coumarin at 90 mg/day compared with 135 mg/day.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10197321</PMID><DateCreated><Year>1999</Year><Month>06</Month><Day>14</Day></DateCreated><DateCompleted><Year>1999</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0024-7766</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>1999</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Lymphology</Title><ISOAbbreviation>Lymphology</ISOAbbreviation></Journal><ArticleTitle>Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer.</ArticleTitle><Pagination><MedlinePgn>3-10</MedlinePgn></Pagination><Abstract><AbstractText>In a randomized, double-blind, parallel group study, we compared the clinical efficacy of coumarin 90 mg/day (Group A) with 135 mg/day (Group B) in 77 women (age 35-65 years) with lymphedema of the upper limb secondary to surgery and irradiation for treatment of breast cancer. During 12 months of coumarin therapy, the arm volume of lymphedema and a clinical score (degree of arm edema, heaviness, hardness, and neuralgia/dysesthesia) were determined. In both groups, the volume of arm lymphedema decreased (14.9% in Group A and 13.2% in Group B) (N.S.), the overall clinical score improved (12.9 +/- 4.3 to 5.7 +/- 3.5 in Group A and from 11.7 +/- 3.7 to 4.7 +/- 3.9 in Group B) (N.S.), and the overall efficacy of coumarin was similarly good or excellent (71.9% in Group A and 68.6% in Group B) (N.S.). Only mild to moderate side effects of drug therapy were recorded. Coumarin prevents a spontaneous trend toward an increase in arm lymphedema after treatment of breast cancer, decreases the severity of local symptoms, and overall improves the quality of life. No difference was found between the apparent benefits of coumarin at 90 mg/day compared with 135 mg/day.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burgos</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratorios Knoll, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcaide</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Alcoba</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Azcona</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Garrido</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lorente</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Murillo</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Olsina-Pavia</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Olsina-Kissler</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Samaniego</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Serra</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lymphology</MedlineTA><NlmUniqueID>0155112</NlmUniqueID><ISSNLinking>0024-7766</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003374">Coumarins</NameOfSubstance></Chemical><Chemical><RegistryNumber>A4VZ22K1WT</RegistryNumber><NameOfSubstance UI="C030123">coumarin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lymphology. 1999 Mar;32(1):1-2</RefSource><PMID Version="1">10197320</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001132" MajorTopicYN="N">Arm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003374" MajorTopicYN="N">Coumarins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>4</Month><Day>10</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>4</Month><Day>10</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10197321</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 004C93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:10197321
|texte= Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:10197321" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |